Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
Patients with relapsed or chemotherapy-refractory SCLC have a dismal prognosis.
Unfortunately, available treatments result in few durable responses. Pemetrexed is a
well-tolerated agent, which is active in NSCLC. Since chemotherapy agents, which are active
in NSCLC, are usually also active in SCLC, this trial will examine the efficacy and activity
of pemetrexed in this palliative setting